Precision treatment of digestive system disorders

Applying specialist knowledge to develop small molecule antagonists of genetically-validated target GPR35
bt_bb_section_bottom_section_coverage_image
 

A competitor differentiated approach

Guided by human genetics, proprietary bioinformatics and pharmacology we are deploying GPR35 antagonism as a differentiated approach to treatment of disease

 

 

Founded upon a deep understanding of the biology of GPR35

We are a group of GPR35 and drug discovery specialists applying our knowledge to develop small molecule antagonists of the GPCR GPR35 for the treatment of serious digestive system disorders with high unmet clinical need

Founded upon a deep understanding of the biology of GPR35

Our Expertise

Established in 2021 by a team of experienced pharmaceutical industry professionals and biotech entrepreneurs

Latest News

£495k Grant Awarded by Innovate UK

£495k Grant Awarded by Innovate UK

ThirtyFiveBio Limited, a biotechnology company developing first-in-class small molecule inhibitors of G protein-coupled receptor 35 (GPR35) for the treatment of...
Read More
Data debut: AACR 2023 Poster

Data debut: AACR 2023 Poster

ThirtyFiveBio were delighted to make our data debut at the American Association for Cancer Research (AACR) 2023 conference. CEO, James...
Read More
ThirtyFiveBio Stealth Emergence

ThirtyFiveBio Stealth Emergence

ThirtyFiveBio Limited, a biotechnology company developing first-in-class small molecule inhibitors of G protein-coupled receptor 35 (GPR35) for the treatment of...
Read More